Magdalena holds an MSc in Pharmaceutical Bioscience and an interdisciplinary PhD merging the fields of psychiatry, immunology and neuropharmacology. Her previous research focused on metabolic and immunologic changes in psychotic disorders. She is now focusing on science writing, allowing her to culture her passion for medical science and human health.
Men would be willing to pay up to $2,000 of their own money to get a more accurate test to detect — or rule out — prostate cancer. This was ... Read more
The U.S. Preventive Services Task Force (USPSTF) has developed a Draft Recommendation Statement of prostate cancer screening using PSA (prostate-specific antigen), now stating that PSA-based screening is recommended in certain ... Read more
Active surveillance of low-risk prostate cancer is as good as treating it in many cases, and spares patients such distressing treatment side effects as sexual-functioning problems, according to a study ... Read more
A study of Cometriq (cabozantinib) in mice with aggressive prostate cancer may explain why a previous clinical trial of the drug failed to treat human prostate cancer. Researchers demonstrated that ... Read more
A new approach to mathematical modeling of prostate cancer has made it possible to spot potentially life-threatening tumors among the ones that are less threatening, allowing physicians to selectively offer ... Read more
Researchers have pinpointed a naturally occurring molecule that limits the invasive capacity of prostate cancer, suggesting that treating patients with a man-made version of the factor could prevent the cancer ... Read more
The presence of molecular tags on a gene may be a new marker for predicting a prostate cancer’s aggressiveness and likelihood of recurrence, and help to identify those patients who would benefit ... Read more
Researchers are one step closer to identifying those men at risk of dying from their prostate cancer, having found that mutations in three well-known cancer genes are linked to a worse prognosis. ... Read more
Men treated with testosterone-lowering drugs for their prostate cancer are more than twice as likely to develop dementia as those not receiving such treatment, according to a study that reviewed the ... Read more
Genetic analysis of a prostate cancer can be misleading if it is based on only one biopsy, according to a study that found large differences in how aggressive different tumors ... Read more
